About: China Tongxinluo study for myocardial protection in patients with acute myocardial infarction (CTS-AMI): Rationale and Design of a Randomized, double-blind, placebo-controlled, multi-center clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: China Tongxinluo study for myocardial protection in patients with acute myocardial infarction (CTS-AMI): Rationale and Design of a Randomized, double-blind, placebo-controlled, multi-center clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	China Tongxinluo study for myocardial protection in patients with acute myocardial infarction (CTS-AMI): Rationale and Design of a Randomized, double-blind, placebo-controlled, multi-center clinical trial
Creator	Li, Xiangdong Zhang, Jun Zhang, Tao Liu, Chen Xu, Yi Li, Jia Wu, Yuan Zhang, Haitao Jiang, Lin Peterson, Eric Yao, Chen Chen, Guihao Dong, Qiuting Dou, Kefei Gao, Runlin Gao, Xiaojin Jin, Chen Liang, Yan Song, Guangyuan Tang, Ruijie Xian, Ying Xu, Lianjun Yan, Hongbing Yang, Jingang Yang, Yanmin Yang, Yuejin You, Shijie Zhang, Wenjia
Source	Elsevier; Medline; PMC
abstract	Abstract Background Acute ST-segment elevation myocardial infarction (STEMI) remains a serious life-threatening event. Despite coronary revascularization, patients might still suffer from poor outcomes caused by myocardial no-reflow and ischemic/reperfusion injury. Tongxinluo (TXL), a traditional Chinese medicine, has been preliminarily demonstrated to reduce myocardial no-reflow and ischemic/reperfusion injury. We further hypothesize that TXL treatment is also effective in reducing clinical endpoints for the patients with STEMI. Methods and Results. The CTS-AMI trial is a prospective, randomized, double-blind, placebo-controlled, multi-center clinical study in China. An estimated 3796 eligible patients with STEMI from about 120 centers are randomized 1:1 ratio to TXL or placebo groups. All enrolled patients are orally administrated a loading dose of 8 capsules of TXL or placebo together with dual anti-platelet agents on admission, followed by 4 capsules three times a day until 12months. The primary endpoint is 30-day major adverse cardiovascular and cerebrovascular events (MACCE), a composite of cardiac death, myocardial re-infarction, emergency coronary revascularization, and stroke. Secondary endpoints include each component of the primary endpoint, 1-year MACCE and other efficacy and safety parameters. Conclusion Results of CTS-AMI trial will determine the clinical efficacy and safety of traditional Chinese medicine TXL capsule in the treatment of STEMI patients in the reperfusion era.
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1016/j.ahj.2020.06.011
bibo:pmid	32679281
has license	els-covid
sha1sum (hex)	0b4b883e04ff89a351b807f610757b993889dd01
schema:url	https://doi.org/10.1016/j.ahj.2020.06.011
resource representing a document's title	China Tongxinluo study for myocardial protection in patients with acute myocardial infarction (CTS-AMI): Rationale and Design of a Randomized, double-blind, placebo-controlled, multi-center clinical trial
has PubMed Central identifier	PMC7305744
has PubMed identifier	32679281
schema:publication	Am Heart J
resource representing a document's body	covid:0b4b883e04ff89a351b807f610757b993889dd01#body_text
is schema:about of	named entity 'ischemic' named entity 'myocardial' named entity 'double-blind' named entity 'infarction' named entity 'China' named entity 'ENDPOINTS' named entity 'BACKGROUND' named entity 'PATIENTS' named entity 'REMAINS' covid:arg/0b4b883e04ff89a351b807f610757b993889dd01 named entity 'hypothesize' named entity 'effective' named entity 'coronary' named entity 'STEMI' named entity 'TXL' named entity 'infarction' named entity 'patients' named entity 'clinical trial' named entity 'Randomized' named entity 'Design' named entity 'reperfusion injury' named entity 'traditional Chinese medicine' named entity 'TXL' named entity 'coronary revascularization' named entity 'clinical trial' named entity 'Acute Myocardial Infarction' named entity 'preliminary screening' named entity 'CRF' named entity 'randomized, double-blind' named entity 'TCM' named entity 'follow-up' named entity 'reperfusion therapy' named entity 'stroke' named entity 'follow-up' named entity 'placebo' named entity 'red blood cells' named entity 'TCM' named entity 'extravasation' named entity 'infarction' named entity 'STEMI' named entity 'AEs' named entity 'significant difference' named entity 'coronary artery' named entity 'life-threatening disease' named entity 'reperfusion' named entity 'TXL' named entity 'clinical study' named entity 'statistically significant' named entity 'follow-up' named entity 'thrombolysis' named entity 'ECG' named entity 'double-blind, placebo-controlled' named entity 'capsules' named entity 'laboratory tests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software